Upper Urinary Tract Carcinoma In Situ

2018 ◽  
pp. 85-95
Author(s):  
Jay D. Raman ◽  
Joshua L. Warrick ◽  
Grant P. Redrow ◽  
Surena F. Matin
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Upper Urinary Tract Carcinoma

Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction

2017 ◽  
Vol 197 (2) ◽  
pp. 287-295 ◽  
Author(s):  
Grant P. Redrow ◽  
Charles C. Guo ◽  
Maurizio A. Brausi ◽  
Jonathan A. Coleman ◽  
Mario I. Fernandez ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Current Knowledge ◽  
Upper Urinary Tract ◽  
Future Direction ◽  
Upper Urinary Tract Carcinoma

Long-term outcome of upper urinary tract carcinoma in situ: Effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy

2006 ◽  
Vol 13 (4) ◽  
pp. 340-344 ◽  
Author(s):  
YOSHIYUKI KOJIMA ◽  
KEIICHI TOZAWA ◽  
NORIYASU KAWAI ◽  
SHOICHI SASAKI ◽  
YUTARO HAYASHI ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Upper Urinary Tract Carcinoma

Clinical impact of Bacillus Calmette-Guérin (BCG) Therapy on prognosis in patients with carcinoma in situ (CIS) of the upper urinary tract: A retrospective comparison with nephroureterectomy.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 417-417
Author(s):  
Takahiro Yoneyama ◽  
Osamu Soma ◽  
Yuuichiro Suzuki ◽  
Tohru Yoneyama ◽  
Kazuyuki Mori ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Adverse Events ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin ◽  
Radical Nephroureterectomy ◽  
Bcg Therapy ◽  
The Impact ◽  
Upper Urinary Tract Carcinoma

417 Background: Clinical benefit of bacillus Calmette-Guérin (BCG) therapy for the management of upper urinary tract carcinoma in situ (CIS) remain unclear. We investigated safety and long-term oncological outcome of BCG therapy for upper urinary tract CIS compared with nephroureterectomy. Methods: We treated consecutive 490 patients with upper urinary tract carcinoma Aomori, Japan. We retrospectively reviewed the post-treatment course of 60 patients with CIS of the upper urinary tract who had undergone either a radical nephroureterectomy (RNU group) or BCG therapy (BCG group). Clinical effectiveness, safety, and oncological outcomes were compared between the groups. Multivariate Cox regression analysis via inverse propensity treatment weighted (IPTW) methods was performed to identify the impact of BCG therapy on prognosis. Results: The number of patients in RNU and BCG groups were 22 and 38, respectively. Median follow-up was 59 months in this cohort. There was no significant difference in background of patients including age, sex, performance status between the groups. The reason of selection for BCG therapy were bilateral CIS of upper urinary tract (50%), solitary kidney (26%), and others (24%). The cytology became negative in 30 (79%) patients after 6-week course of BCG. BGC related adverse events were observed 92% of patients. Most common events were cystitis (76%) followed by fever (50%). Two patients experienced grade 3 sepsis after BCG therapy. 13 patients (43%) experienced tumor recurrence after BCG therapy. There were no significant differences in recurrence-free survival, cancer-specific survival, and overall survival between the RNU and BCG groups. Multivariate analysis revealed BCG therapy did not worse the prognosis of those patients. Conclusions: Although mild adverse events were frequented in BCG therapy for CIS of the upper urinary tract, it might be a useful alterative in patients with CIS of the upper urinary tract who are ineligible for radical nephroureterectomy. Further prospective studies are needed to confirm the benefits of BCG therapy for CIS of the upper urinary tract.

Bropirimine immunotherapy of upper urinary tract carcinoma in situ

Urology ◽  
1996 ◽  
Vol 48 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Michael F. Sarosdy ◽  
Louis L. Pisters ◽  
Peter R. Carroll ◽  
Mitchell C. Benson ◽  
Timothy D. Moon ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Upper Urinary Tract Carcinoma

Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract

2002 ◽  
Vol 9 (12) ◽  
pp. 677-680 ◽  
Author(s):  
HIDEAKI MIYAKE ◽  
HIROSHI ETO ◽  
SHOJI HARA ◽  
HIROSHI OKADA ◽  
SADAO KAMIDONO ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Clinical Outcome ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin
Sign in / Sign up

Export Citation Format

Share Document